Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Subcutaneous hydrocortisone Clear all
Completed Not applicable Interventional

Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia

NCT00529841
View directory record Official record
Conditions
Adrenal Hyperplasia, Congenital
Interventions
Hydrocortisone sodium acetate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2015 · Synced Sep 13, 2026, 4:44 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

NCT04037605
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 1 Interventional Results available

Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia

NCT03718234
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, Hyperplasia, Adrenal Hyperplasia, Congenital Disorders, Adrenocortical Hyperfunction, Disorders of Sex Development, Urogenital Abnormalities, Genetic Diseases, Inborn, Steroid Metabolic Diseases, Inborn, Adrenal Gland Disease, Hydrocortisone
Interventions
Subcutaneous hydrocortisone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
4 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 13, 2026, 4:44 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes

NCT01265017
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

ALL Adult Consortium Trial: Adult ALL Trial

NCT00476190
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Doxorubicin, Cytarabine, Methotrexate, Vincristine, Cyclophosphamide, Methylprednisone, Hydrocortisone Sodium Succinate, Dexamethasone, 6-MP, PEG-Asparaginase, Imatinib, Etoposide, Radiation Therapy, E. coli Asparaginase
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 13, 2026, 4:44 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

NCT03793478
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Quizartinib, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Month to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

NCT05436535
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
433 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 13, 2026, 4:44 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

NCT07494084
View directory record Official record
Conditions
Shift Work Schedule, Circadian Rhythm, Insulin Resistance, Circadian Misalignment
Interventions
Metyrapone And Hydrocortisone, Dextrose, insulin
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

NCT00434148
View directory record Official record
Conditions
Cushing's Disease
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
10
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia

NCT01859312
View directory record Official record
Conditions
Adrenal Insufficiency, Excess Androgen, Congenital Adrenal Hyperplasia (CAH)
Interventions
Hydrocortisone (Solucortef), Insulin pump (Medtronic)
Drug · Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 13, 2026, 4:44 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

NCT00482053
View directory record Official record
Conditions
Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL), Malignant Lymphoma, Non-Hodgkin
Interventions
Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation (TLI), Rituximab, Carmustine, Etoposide, Filgrastim, Anti-thymocyte globulin (ATG), Cyclosporine, Mycophenolate mofetil (MMF), Cyclophosphamide, Acetaminophen, Diphenhydramine, Hydrocortisone, Methylprednisolone
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 13, 2026, 4:44 PM EDT
Terminated Phase 2 Interventional Results available

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

NCT02419755
View directory record Official record
Conditions
Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Interventions
Bortezomib, Vorinostat, Mitoxantrone, Cytarabine, Methotrexate, Hydrocortisone, Peg-L-Asparaginase, Erwinia L-Asparaginase, Dexamethasone, Mercaptopurine, Doxorubicin
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

NCT02465606
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Encino, California • Granada Hills, California • Mission Viejo, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 13, 2026, 4:44 PM EDT
Recruiting Not applicable Interventional

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

NCT07361874
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
Interventions
Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 13, 2026, 4:44 PM EDT
Terminated Phase 2 Interventional

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer

NCT00447473
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
GM-CSF, Ketoconazole, Mitoxantrone
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 4 Interventional Results available

Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.

NCT01966718
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Repository corticotropin injection
Drug
Lead sponsor
Arthritis Treatment Center, Maryland
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Sep 13, 2026, 4:44 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study

NCT03142893
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
Drug
Lead sponsor
Peter y. Liu
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 13, 2026, 4:44 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT04898894
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia
Interventions
Venetoclax, Selinexor, Cytarabine, Fludarabine, Filgrastim, Methotrexate, methotrexate/hydrocortisone/cytarabine
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 30 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
San Diego, California • Boston, Massachusetts • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 13, 2026, 4:44 PM EDT